Successful targeting of the NRG1 fusion reveals durable response to afatinib in lung adenocarcinoma: a case report

The treatments for advanced non-small cell lung cancer (NSCLC) patients have been improved by developing tyrosine kinase inhibitors (TKIs) as targeted therapies. Oncogenic gene fusions resulting from structural DNA rearrangements have been proposed as a unique class of oncogenic drivers and therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Xiaokang, Zhang, Dongqing, Shi, Mengru, Wang, Fang, Li, Yuping, Lin, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573434/
https://www.ncbi.nlm.nih.gov/pubmed/34805369
http://dx.doi.org/10.21037/atm-21-3923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573434/
https://www.ncbi.nlm.nih.gov/pubmed/34805369
http://dx.doi.org/10.21037/atm-21-3923

Ejemplares similares